The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
 
Li Bai
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Aibing Xu
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Jian Wu
No Relationships to Disclose
 
Guoliang Shao
No Relationships to Disclose
 
Lijie Song
No Relationships to Disclose
 
Xiaoping Jin
Employment - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Weifeng Song
Employment - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Baiyong Li
Employment - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Yu Xia
Employment - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Shunchang Jiao
No Relationships to Disclose